Effect of Tocilizumab Use on Mortality in COVID-19 Patients Admitted to Intensive Care Unit
Aim: Coronavirus disease 2019 (COVID-19) mostly proceeds with mild respiratory symptoms, but sometimes severe pneumonia, cytokine storm, and acute respiratory distress syndrome can develop. Anti-cytokine treatments are being tried for cytokine storm. In this study, we aimed to examine the effect of tocilizumab on mortality associated with COVID-19. Material and Methods: The study included 146 patients with moderate-to-severe acute respiratory distress syndrome diagnosed with COVID-19. The patients were divided into two groups, receiving only standard treatment (ST group, n=44), and tocilizumab treatment in addition to standard treatment (TCZ group, n=102). Groups were compared in terms of demographic, clinic, and laboratory data. Also, mortality rates were determined to detect the effect of tocilizumab on mortality. Results: Overall, 36.3% (n=53) of the patients were female, 63.7% (n=93) were male, and the mean age was 69.5±14.2 years. The mortality rate was 29.4% (n=30) in the TCZ group and 52.3% (n=23) in the ST group (p=0.009). While C-reactive protein, fibrinogen, and lactate levels on admission to the intensive care unit (ICU) were similar across the groups, the TCZ group had higher ferritin levels (p=0.006). On discharge from ICU, the TCZ group had a significant decrease in C-reactive protein (p<0.001), while their ferritin levels decreased to levels in the ST group (p=0.134). The absence of tocilizumab in the treatment regimen was associated with a 2.63-fold increase in the mortality risk. Conclusion: Tocilizumab reduces the mortality in COVID-19 patients in ICU. However, further studies are warranted to better elucidate the efficacy and side effects of tocilizumab..
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2022 |
|---|---|
| Erschienen: |
2022 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:24 |
|---|---|
| Enthalten in: |
Düzce Tıp Fakültesi Dergisi - 24(2022), 3, Seite 227-234 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Hasan Ölmez [VerfasserIn] |
|---|
| Links: |
doi.org [kostenfrei] |
|---|
| Themen: |
Covid-19; |
|---|
| doi: |
10.18678/dtfd.1108303 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
DOAJ020766890 |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | DOAJ020766890 | ||
| 003 | DE-627 | ||
| 005 | 20240412103635.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 230226s2022 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.18678/dtfd.1108303 |2 doi | |
| 035 | |a (DE-627)DOAJ020766890 | ||
| 035 | |a (DE-599)DOAJd0622d7fae774e37a669c317b1f62872 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 050 | 0 | |a R5-920 | |
| 100 | 0 | |a Hasan Ölmez |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Effect of Tocilizumab Use on Mortality in COVID-19 Patients Admitted to Intensive Care Unit |
| 264 | 1 | |c 2022 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a Computermedien |b c |2 rdamedia | ||
| 338 | |a Online-Ressource |b cr |2 rdacarrier | ||
| 520 | |a Aim: Coronavirus disease 2019 (COVID-19) mostly proceeds with mild respiratory symptoms, but sometimes severe pneumonia, cytokine storm, and acute respiratory distress syndrome can develop. Anti-cytokine treatments are being tried for cytokine storm. In this study, we aimed to examine the effect of tocilizumab on mortality associated with COVID-19. Material and Methods: The study included 146 patients with moderate-to-severe acute respiratory distress syndrome diagnosed with COVID-19. The patients were divided into two groups, receiving only standard treatment (ST group, n=44), and tocilizumab treatment in addition to standard treatment (TCZ group, n=102). Groups were compared in terms of demographic, clinic, and laboratory data. Also, mortality rates were determined to detect the effect of tocilizumab on mortality. Results: Overall, 36.3% (n=53) of the patients were female, 63.7% (n=93) were male, and the mean age was 69.5±14.2 years. The mortality rate was 29.4% (n=30) in the TCZ group and 52.3% (n=23) in the ST group (p=0.009). While C-reactive protein, fibrinogen, and lactate levels on admission to the intensive care unit (ICU) were similar across the groups, the TCZ group had higher ferritin levels (p=0.006). On discharge from ICU, the TCZ group had a significant decrease in C-reactive protein (p<0.001), while their ferritin levels decreased to levels in the ST group (p=0.134). The absence of tocilizumab in the treatment regimen was associated with a 2.63-fold increase in the mortality risk. Conclusion: Tocilizumab reduces the mortality in COVID-19 patients in ICU. However, further studies are warranted to better elucidate the efficacy and side effects of tocilizumab. | ||
| 650 | 4 | |a covid-19; | |
| 650 | 4 | |a cytokine storm; | |
| 650 | 4 | |a tocilizumab; | |
| 650 | 4 | |a mortality; | |
| 650 | 4 | |a interleukin 6. | |
| 650 | 4 | |a sitokin fırtınası; | |
| 650 | 4 | |a tosilizumab; | |
| 650 | 4 | |a mortalite; | |
| 650 | 4 | |a interlökin 6. | |
| 653 | 0 | |a Medicine | |
| 653 | 0 | |a R | |
| 653 | 0 | |a Medicine (General) | |
| 700 | 0 | |a Mustafa Tosun |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i In |t Düzce Tıp Fakültesi Dergisi |d Duzce University, 2009 |g 24(2022), 3, Seite 227-234 |w (DE-627)DOAJ000142395 |x 1307671X |7 nnns |
| 773 | 1 | 8 | |g volume:24 |g year:2022 |g number:3 |g pages:227-234 |
| 856 | 4 | 0 | |u https://doi.org/10.18678/dtfd.1108303 |z kostenfrei |
| 856 | 4 | 0 | |u https://doaj.org/article/d0622d7fae774e37a669c317b1f62872 |z kostenfrei |
| 856 | 4 | 0 | |u https://dergipark.org.tr/en/download/article-file/2394017 |z kostenfrei |
| 856 | 4 | 2 | |u https://doaj.org/toc/1307-671X |y Journal toc |z kostenfrei |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_DOAJ | ||
| 951 | |a AR | ||
| 952 | |d 24 |j 2022 |e 3 |h 227-234 | ||